Prospective Cohort of Patients With Hepatocellular Carcinoma in France

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 14, 2020

Keywords

ClinConnect Summary

The CHIEF project is a clinical trial designed to gather important information about patients with hepatocellular carcinoma (HCC), a type of liver cancer that is often linked to liver disease. In France, there are about 8,500 new cases of HCC each year, and unfortunately, many patients face a challenging prognosis with a low survival rate. This study aims to collect data from 5,000 patients over two years, tracking their health and treatment for up to five years. By doing this, researchers hope to improve understanding of HCC and develop better ways to diagnose and treat it.

To participate in this trial, you need to have a new or suspected diagnosis of HCC, or be receiving treatment for a recurrence or worsening of the disease. The study is open to all adults, but those with serious other health conditions that could threaten their lives in the short term, or vulnerable populations like minors or those under guardianship, will not be included. If you join the study, you can expect to provide some information about your health and undergo regular follow-up visits to help researchers learn more about HCC and improve future care for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New cases of HCC
• • suspected case of HCC regardless of the cause, stage, treatment
• • Known HCC: drug treatment for recurrence or progression
• Exclusion Criteria:
• • Associated serious condition threatening life in the short term (with the exception of liver disease itself)
• • So-called vulnerable populations: minors, persons under guardianship or temporary guardianship, or person deprived of their liberty by an administrative or judicial decision